American Society of Hematology

Figure 3.

$Figure 3. Identification of the TME binding proteins. (A) Binding of TME-DNA chromatographed fractions of nuclear extracts from HEL cells. In the lane labeled NE, 6 μg nuclear extract before the purification was used. In the lanes labeled FT and nos. 6 to 17, the flow through fraction and the fractions nos. 6 to 17 were used, respectively. The bracket indicates the specific shifted bands. (B) Identification of the binding proteins by Western blotting. The purified proteins were analyzed by Western blotting with antibodies to homeodomain proteins (left panels) and to transcription factors expressed in megakaryocytes (right panels). In the case of the antibodies for which no signal was detected, the activities of these antibodies were confirmed by Western blotting using recombinant proteins (HOXA9 and NF-E2p45) or cell extracts (bottom panel). Molecular weight is indicated to the right of each panel.$

Identification of the TME binding proteins. (A) Binding of TME-DNA chromatographed fractions of nuclear extracts from HEL cells. In the lane labeled NE, 6 μg nuclear extract before the purification was used. In the lanes labeled FT and nos. 6 to 17, the flow through fraction and the fractions nos. 6 to 17 were used, respectively. The bracket indicates the specific shifted bands. (B) Identification of the binding proteins by Western blotting. The purified proteins were analyzed by Western blotting with antibodies to homeodomain proteins (left panels) and to transcription factors expressed in megakaryocytes (right panels). In the case of the antibodies for which no signal was detected, the activities of these antibodies were confirmed by Western blotting using recombinant proteins (HOXA9 and NF-E2p45) or cell extracts (bottom panel). Molecular weight is indicated to the right of each panel.

This Feature Is Available To Subscribers Only